← 產業報告目錄

Stem Cell Therapy Market by Cell Source (Adipose Tissue, Bone Marrow, Placenta, Umbilical Cord, iPSC), Type (Autologus Stem Cell), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological), End User - Global Forecast to 2035

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-06-15頁數 281報告編號 BT5049

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The stem cell therapy market is projected to reach USD 3.65 billion by 2035 from USD 0.48 billion in 2026, at a CAGR of 25.3% from 2026 to 2035. The market is driven by the expanding pipeline of stem cell-based therapies, increasing demand for regenerative treatments, and growth in advanced modalities such as iPSC-derived therapies and allogeneic cell products. Market estimates indicate robust expansion through 2035, supported by technological advancements in cell processing and manufacturing and rising clinical adoption of approved stem cell therapies. However, high manufacturing and treatment costs, complex regulatory pathways across regions, scalability challenges from bench to commercial manufacturing, and the need for specialized infrastructure and expertise are expected to restrain broader market growth. “The induced pluripotent stem cell (iPSC) segment is projected to grow at the highest CAGR in the stem cell therapy market over the forecast period.” Based on cell source, the stem cell therapy market is broadly segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, induced pluripotent stem cells, embryonic stem cells, tissue-specific stem cells, and other cell sources. The induced pluripotent stem cell (iPSC) segment is expected to grow at the highest CAGR in the stem cell therapy market because it is moving from a high-potential research platform toward early commercial validation, while still starting from a relatively low revenue base. iPSCs provide a renewable and scalable cell source that can be differentiated into multiple therapeutic cell types, including dopaminergic neurons, cardiomyocytes, retinal cells, pancreatic beta-like cells, and other tissue-specific cells, making them attractive for large unmet-need indications such as Parkinson’s disease, heart failure, diabetes, retinal disorders, and other degenerative diseases. “Allogeneic stem cell therapy accounted for the largest share of the stem cell therapy market, by type, in 2025.” Based on type, the global stem cell therapy market is segmented into allogeneic and autologous stem cell therapies. The allogeneic stem cell therapy segment accounted for the largest share of the stem cell therapy market in 2025, due to its scalability, off-the-shelf availability, and cost advantages in commercial manufacturing. These therapies enable standardized production and broader patient access essential for clinical and commercial applications. Additionally, the expanding pipeline of allogeneic cell therapy candidates, increasing regulatory approvals, and growing commercial-scale manufacturing activities continue to strengthen the segment’s leading market position globally. “Europe is projected to grow at the highest CAGR in the stem cell therapy market from 2026 to 2035.” The stem cell therapy market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, Europe is projected to be the fastest-growing region in the stem cell therapy market due to its strong regulatory framework for advanced therapy medicinal products, expanding transplant and cell therapy infrastructure, high clinical trial activity, and rising investment in scalable ATMP manufacturing. The EMA classifies substantially manipulated or non-homologous stem-cell products as ATMPs and has a dedicated Committee for Advanced Therapies, creating a clear pathway for stem cell-based product assessment, scientific advice, and market authorization. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%) List of Companies Profiled in the Report Key players in the global stem cell therapy market include Vericel Corporation (US), Mesoblast (Australia), MEDIPOST (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Anterogen Co., Ltd. (South Korea), CorestemChemon Inc. / Corestem, Inc. (South Korea), Vertex Pharmaceuticals (US), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), Stempeutics Research Pvt. Ltd. (India), Cipla Limited (India), Bayer AG (Germany), Aspen Neuroscience (US), Longeveron Inc. (US), and Smith+Nephew (UK). Research Coverage This research report categorizes the stem cell therapy market by Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Placenta/Umbilical Cord-Derived Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Tissue-Specific Stem Cells, Other Cell Sources), Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), Therapeutic Application (Musculoskeletal Disorders, Wounds & Surgeries, Inflammatory & Autoimmune Diseases, Cardiovascular Diseases, Neurological Disorders, Diabetes & Metabolic Diseases, Other Therapeutic Applications), End User (Hospitals, Specialty / Stem Cell Clinics, Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East, and Africa) The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the stem cell therapy market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the stem cell therapy market. This report covers competitive analysis of top players and upcoming startups in the stem cell therapy market ecosystem. Key Benefits of Buying the Report The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall stem cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: o Analysis of key drivers (rising regulatory approvals are validating stem cell therapy as a viable commercial treatment class, high unmet needs in rare and chronic diseases are driving demand for curative therapies, gene-modified HSPC therapies are creating a high-value segment in the stem cell therapy market, allogeneic and off-the-shelf approaches are improving scalability over autologous therapies), restraints (high therapy price and uncertain reimbursement remain the largest restraints on market adoption, manufacturing complexity and high cost of goods limit scalability and margins, inconsistent clinical evidence in some regenerative indications reduces payer and physician confidence, regulatory heterogeneity across countries complicates global commercialization.), opportunities (iPSC-derived therapies offer long-term opportunities for scalable cell replacement, allogeneic MSC and progenitor-cell platforms can expand access beyond individualized therapy, expansion into neurological, cardiovascular, metabolic, and ocular diseases can broaden market potential, Gene-modified HSPC therapies can expand into younger patients, additional hemoglobinopathies, immune diseases, and metabolic diseases), and challenges (potency testing and product characterization challenges, demonstrating clear clinical efficacy is difficult in heterogeneous regenerative indications, manufacturing comparability after process changes can delay scale-up and approval, patient referral, eligibility, and treatment readiness can slow real-world uptake o Product Development/Innovation: Detailed insights into upcoming technologies and research & development activities in the global stem cell therapy market o Market Development: Comprehensive information about lucrative markets (the report analyzes the market across varied regions) o Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global stem cell therapy market o Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players (a detailed analysis of the key industry players has been carried out to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investments & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the global stem cell therapy market)
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 31 1.3.1 MARKETS SEGMENTATION AND REGIONAL SCOPE 31 1.4 INCLUSIONS & EXCLUSIONS 32 1.4.1 YEARS CONSIDERED 32 1.4.2 CURRENCY CONSIDERED 33 1.5 STAKEHOLDERS 33 1.6 SUMMARY OF CHNAGES 33 2 EXECUTIVE SUMMARY 35 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 38 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40 3 PREMIUM INSIGHTS 41 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN STEM CELL THERAPY MARKET 41 3.2 STEM CELL THERAPY MARKET, BY TYPE AND REGION 42 3.3 STEM CELL THERAPY MARKET, BY COUNTRY 42 3.4 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2026 VS 2035 43 4 MARKET OVERVIEW 44 4.1 INTRODUCTION 44 4.2 MARKET DYNAMICS 44 4.2.1 DRIVERS 45 4.2.1.1 Rising regulatory approvals validating stem cell therapies 45 4.2.1.2 Unmet needs in rare and chronic diseases driving demand for curative therapies 46 4.2.1.3 Allogeneic and off-the-shelf approaches improving scalability over autologous therapies 46 4.2.2 RESTRAINTS 46 4.2.2.1 High therapy price and uncertain reimbursement limiting adoption 46 4.2.2.2 Manufacturing complexity and high cost of goods limiting scalability and margins 47 4.2.2.3 Inconsistent clinical evidence reducing payer and physician confidence 47 4.2.2.4 Regulatory inconsistency across countries complicating global commercialization 48 4.2.3 OPPORTUNITY 48 4.2.3.1 iPSC-derived therapies offering long-term opportunities for scalable cell replacement 48 4.2.3.2 Allogeneic MSC and progenitor-cell platforms can support expansion beyond personalized treatment models 48 4.2.3.3 Expansion into neurological, cardiovascular, and metabolic diseases 49 4.2.4 CHALLENGES 49 4.2.4.1 Potency testing and product characterization challenges 49 4.2.4.2 Difficulty in demonstrating clear clinical efficacy in heterogeneous regenerative indications 49 4.2.4.3 Manufacturing comparability challenges following process changes may delay scale-up and regulatory approval 49 4.3 UNMET NEEDS AND WHITE SPACES 50 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51 5 INDUSTRY TRENDS 52 5.1 PORTER'S FIVE FORCES ANALYSIS 52 5.1.1 THREAT OF NEW ENTRANTS 53 5.1.2 THREAT OF SUBSTITUTES 53 5.1.3 BARGAINING POWER OF BUYERS 53 5.1.4 BARGAINING POWER OF SUPPLIERS 53 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54 5.2 MACROECONOMIC OUTLOOK 54 5.2.1 INTRODUCTION 54 5.2.2 GDP TRENDS AND FORECAST 55 5.2.3 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55 5.2.4 TRENDS IN GLOBAL STEM CELL THERAPY MARKET 55 5.3 VALUE CHAIN ANALYSIS 56 5.4 ECOSYSTEM ANALYSIS 58 5.5 PRICING ANALYSIS 59 5.5.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 59 5.5.2 INDICATIVE SELLING PRICE, BY REGION 60 5.6 KEY CONFERENCES & EVENTS 61 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 62 5.8 INVESTMENT/FUNDING ACTIVITY 62 5.9 CASE STUDY ANALYSIS 63 5.10 IMPACT OF 2025 US TARIFF - STEM CELL THERAPY MARKET 64 5.10.1 INTRODUCTION 64 5.10.2 KEY TARIFF RATES 64 5.10.3 PRICE IMPACT ANALYSIS 65 5.10.4 IMPACT ON COUNTRY/REGION 66 5.10.4.1 North America 66 5.10.4.2 Europe 66 5.10.4.3 Asia Pacific 67 5.10.5 IMPACT ON END-USE INDUSTRIES 67 5.10.5.1 Hospitals 67 5.10.5.2 Specialty/Stem cell clinics 68 5.10.5.3 Other end users 68 5.11 SUPPLY CHAIN ANALYSIS 68 5.12 KEY STEM CELL THERAPY MANUFACTURING CAPACITY ADDITIONS 70 5.12.1 KEY CDMO CAPACITY ADDITIONS 70 5.12.2 KEY SPONSOR CAPACITY ADDITIONS 70 5.12.3 GLOBAL KEY STEM CELL THERAPY PRODUCT SALES 72 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS 73 6.1 TECHNOLOGY ANALYSIS 73 6.1.1 KEY TECHNOLOGIES 73 6.1.1.1 Bioreactor systems 73 6.1.1.2 Cell expansion & differentiation platforms 73 6.1.2 ADJACENT TECHNOLOGIES 73 6.1.2.1 Reprogramming & gene engineering tools 73 6.1.2.2 Downstream processing technologies 73 6.1.3 COMPLEMENTARY TECHNOLOGIES 74 6.1.3.1 Advanced cell culture consumables 74 6.1.3.2 Automation and robotics 74 6.2 TECHNOLOGY/PRODUCT ROADMAP 74 6.3 PIPELINE ANALYSIS 74 6.4 FUTURE APPLICATIONS 77 6.5 IMPACT OF AI/GEN AI ON STEM CELL THERAPY MARKET 77 6.5.1 TOP USE CASES AND MARKET POTENTIAL 78 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN STEM CELL THERAPY MARKET 78 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 78 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN STEM CELL THERAPY MARKET 79 6.6 SUCCESS STORIES AND REAL WORLD APPLICATIONS 80 7 SUSTAINABILITY AND REGULATORY LANDSCAPE 81 7.1 REGIONAL REGULATIONS AND COMPLIANCE 81 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 7.1.2 REGULATORY FRAMEWORK 84 7.1.3 INDUSTRY STANDARDS 84 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 85 7.3 CERTIFICATIONS, LABELING & ECO-STANDARDS 85 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 88 8.1 DECISION-MAKING PROCESS 88 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 89 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 89 8.2.2 KEY BUYING CRITERIA, BY END USER 89 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 91 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 91 8.5 MARKET PROFITABILITY 92 9 STEM CELL THERAPY MARKET BY CELL SOURCE 93 9.1 INTRODUCTION 94 9.2 ADIPOSE TISSUE-DERIVED MSCS 94 9.2.1 GROWING ADOPTION OF ADIPOSE-DERIVED MSC THERAPIES IN RECONSTRUCTIVE SURGERY AND AESTHETIC MEDICINE DRIVING MARKET 94 9.3 BONE MARROW-DERIVED MSCS 97 9.3.1 ACCELERATING REGULATORY MILESTONES AND EXPANDING INDICATIONS FOR BONE MARROW-DERIVED MSC THERAPIES DRIVING MARKET GROWTH 97 9.4 PLACENTA/UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS 100 9.4.1 EXPANDING CORD BLOOD BANKING INFRASTRUCTURE AND ALLOGENEIC PRODUCT DEVELOPMENT FUELING SEGMENT GROWTH 100 9.5 INDUCED PLURIPOTENT STEM CELLS (IPSCS) 102 9.5.1 BREAKTHROUGH CLINICAL PROGRAMS AND NEXT-GENERATION MANUFACTURING PLATFORMS POSITIONING IPSCS AS TRANSFORMATIVE CELL SOURCE 102 9.6 EMBRYONIC STEM CELLS (ESCS) 105 9.6.1 LANDMARK REGULATORY APPROVALS AND CLINICAL VALIDATION OF ESC-DERIVED ISLET CELL THERAPIES CATALYZING GROWTH 105 9.7 TISSUE-SPECIFIC STEM CELLS 108 9.7.1 ESTABLISHED COMMERCIAL PRODUCTS AND EXPANDING CLINICAL APPLICATIONS FUELING MARKET GROWTH 108 9.8 OTHER CELL SOURCES 110 10 STEM CELL THERAPY MARKET BY TYPE 113 10.1 INTRODUCTION 114 10.2 ALLOGENEIC STEM CELL THERAPY 114 10.2.1 SCALABLE OFF-THE-SHELF MANUFACTURING AND EXPANDING CLINICAL PIPELINES DRIVING RAPID GROWTH 114 10.3 AUTOLOGOUS STEM CELL THERAPY 117 10.3.1 ESTABLISHED COMMERCIAL PRODUCTS AND PATIENT-SPECIFIC IMMUNOLOGICAL ADVANTAGES TO SUSTAIN STEADY GROWTH 117 11 STEM CELL THERAPY MARKET BY THERAPEUTIC APPLICATION 120 11.1 INTRODUCTION 121 11.2 MUSCULOSKELETAL DISORDERS 121 11.2.1 RISING GLOBAL PREVALENCE OF OSTEOARTHRITIS AND GROWING ADOPTION OF CELL-BASED CARTILAGE REPAIR THERAPIES DRIVING SEGMENT GROWTH 121 11.3 WOUNDS & SURGERIES 124 11.3.1 EXPANDING APPLICATIONS OF STEM CELL THERAPIES IN WOUND HEALING, BURN TREATMENT, AND SURGICAL RECONSTRUCTION SUPPORTING SEGMENT GROWTH 124 11.4 INFLAMMATORY & AUTOIMMUNE DISEASES 127 11.4.1 EXPANDING CLINICAL VALIDATION OF MSC IMMUNOMODULATORY PROPERTIES AND FDA APPROVAL OF RYONCIL FOR GVHD DRIVING GROWTH 127 11.5 CARDIOVASCULAR DISEASES 129 11.5.1 ADVANCING LATE-STAGE CLINICAL PROGRAMS AND GROWING EVIDENCE FOR MSC-MEDIATED CARDIAC REPAIR SUPPORTING MARKET GROWTH 129 11.6 NEUROLOGICAL DISORDERS 132 11.6.1 BREAKTHROUGH IPSC-DERIVED NEURONAL THERAPIES AND EXPANDING CLINICAL PROGRAMS FOR NEURODEGENERATIVE CONDITIONS DRIVING SEGMENTAL GROWTH 132 11.7 DIABETES & METABOLIC DISEASES 135 11.7.1 TRANSFORMATIVE POTENTIAL OF ESC-DERIVED ISLET CELL THERAPIES FOR TYPE 1 DIABETES FUELING RAPID MARKET GROWTH 135 11.8 OTHER THERAPEUTIC APPLICATIONS 137 12 STEM CELL THERAPY MARKET, BY END USER 140 12.1 INTRODUCTION 141 12.2 HOSPITALS 141 12.2.1 ADVANCED TRANSPLANT INFRASTRUCTURE AND CONCENTRATION OF REGULATORY-APPROVED STEM CELL THERAPY ADMINISTRATION DRIVING GROWTH 141 12.3 SPECIALTY/STEM CELL CLINICS 144 12.3.1 GROWING NUMBER OF DEDICATED REGENERATIVE MEDICINE CENTERS AND EXPANDING AUTOLOGOUS MSC TREATMENT OFFERINGS DRIVING SEGMENTAL GROWTH 144 12.4 OTHER END USERS 146 12.4.1 AMBULATORY SURGICAL CENTERS, ACADEMIC RESEARCH INSTITUTES, AND CELL BANKS EXPANDING STEM CELL THERAPY DELIVERY ECOSYSTEM 146 13 STEM CELL THERAPY MARKET, BY REGION 150 13.1 INTRODUCTION 151 13.2 NORTH AMERICA 151 13.2.1 US 154 13.2.2 CANADA 155   13.3 EUROPE 157 13.3.1 GERMANY 160 13.3.2 UK 161 13.3.3 FRANCE 163 13.3.4 ITALY 164 13.3.5 SPAIN 166 13.3.6 REST OF EUROPE 167 13.4 ASIA PACIFIC 169 13.4.1 CHINA 171 13.4.2 JAPAN 172 13.4.3 INDIA 174 13.4.4 SOUTH KOREA 175 13.4.5 AUSTRALIA 177 13.4.6 REST OF ASIA PACIFIC 178 13.5 LATIN AMERICA 180 13.5.1 BRAZIL 182 13.5.2 MEXICO 183 13.5.3 REST OF LATIN AMERICA 185 13.6 MIDDLE EAST 186 13.6.1 GCC COUNTRIES 188 13.6.1.1 Saudi Arabia 190 13.6.1.2 UAE 191 13.6.1.3 Rest of GCC Countries 193 13.6.2 REST OF MIDDLE EAST 194 13.7 AFRICA 196 14 COMPETITIVE LANDSCAPE 198 14.1 INTRODUCTION 198 14.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 198 14.3 REVENUE ANALYSIS, 2023–2025 199 14.4 MARKET SHARE ANALYSIS, 2025 201 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 203 14.5.1 STARS 203 14.5.2 EMERGING LEADERS 203 14.5.3 PERVASIVE PLAYERS 203 14.5.4 PARTICIPANTS 203 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 205 14.5.5.1 Company footprint 205 14.5.5.2 Region footprint 206 14.5.5.3 Cell source footprint 207 14.5.5.4 Type footprint 208 14.5.5.5 Therapeutic application footprint 209 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 210 14.6.1 PROGRESSIVE COMPANIES 210 14.6.2 RESPONSIVE COMPANIES 210 14.6.3 DYNAMIC COMPANIES 210 14.6.4 STARTING BLOCKS 210 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 212 14.6.5.1 List of key startups/SMEs 212 14.6.5.2 Competitive benchmarking of key startups/SMEs 213 14.7 COMPANY VALUATION & FINANCIAL METRICS 213 14.7.1 FINANCIAL METRICS 214 14.7.2 COMPANY VALUATION 214 14.8 BRAND/PRODUCT COMPARISON 215 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 215 14.9 COMPETITIVE SCENARIO 216 14.9.1 PRODUCT LAUNCHES 216 14.9.2 DEALS 217 15 COMPANY PROFILES 218 15.1 KEY PLAYERS 218 15.1.1 VERICEL CORPORATION 218 15.1.1.1 Business overview 218 15.1.1.2 Products offered 219 15.1.1.3 Recent developments 220 15.1.1.3.1 Product Approval 220 15.1.1.4 MnM view 220 15.1.1.4.1 Key strengths 220 15.1.1.4.2 Strategic choices 220 15.1.1.4.3 Weaknesses & competitive threats 220 15.1.2 MESOBLAST 221 15.1.2.1 Business overview 221 15.1.2.2 Products offered 222 15.1.2.3 Recent developments 223 15.1.2.3.1 Product approval 223 15.1.2.4 MnM view 223 15.1.2.4.1 Key strengths 223 15.1.2.4.2 Strategic choices 223 15.1.2.4.3 Weaknesses & competitive threats 224 15.1.3 JCR PHARMACEUTICALS CO., LTD. 225 15.1.3.1 Business overview 225 15.1.3.2 Products offered 226 15.1.3.3 Product pipeline 227   15.1.3.4 MnM view 227 15.1.3.4.1 Key strengths 227 15.1.3.4.2 Strategic choices 227 15.1.3.4.3 Weaknesses & competitive threats 227 15.1.4 MEDIPOST 228 15.1.4.1 Business overview 228 15.1.4.2 Products offered 229 15.1.4.3 Recent developments 229 15.1.4.3.1 Deals 229 15.1.4.3.2 OTHER DEVELOPMENTS 230 15.1.4.4 MnM view 230 15.1.4.4.1 Key strengths 230 15.1.4.4.2 Strategic choices 230 15.1.4.4.3 Weaknesses & competitive threats 231 15.1.5 CO.DON GMBH 232 15.1.5.1 Business overview 232 15.1.5.2 Products offered 232 15.1.5.3 MnM view 233 15.1.5.3.1 Key strengths 233 15.1.5.3.2 Strategic choices 233 15.1.5.3.3 Weaknesses & competitive threats 233 15.1.6 SMITH+NEPHEW 234 15.1.6.1 Business overview 234 15.1.6.2 Products offered 235 15.1.7 ANTEROGEN CO., LTD. 236 15.1.7.1 Business overview 236 15.1.7.2 Products offered 236 15.1.8 CORESTEMCHEMON INC. 237 15.1.8.1 Business overview 237 15.1.8.2 Products offered 238 15.1.9 VERTEX PHARMACEUTICALS INCORPORATED 239 15.1.9.1 Business overview 239 15.1.9.2 Products offered 240 15.1.9.2.1 Other developments 240 15.1.10 PHARMICELL CO., LTD 241 15.1.10.1 Business overview 241 15.1.10.2 Products offered 241 15.1.10.3 Recent developments 242 15.1.10.3.1 Deals 242 15.1.11 HOLOSTEM TERAPIE AVANZATE SRL 243 15.1.11.1 Business overview 243 15.1.11.2 Products offered 243 15.1.12 STEMPEUTICS RESEARCH PVT LTD. 244 15.1.12.1 Business overview 244 15.1.12.2 Products offered 244 15.1.12.3 Recent developments 245 15.1.12.3.1 Deals 245 15.1.13 CIPLA LIMITED 246 15.1.13.1 Business overview 246 15.1.13.2 Products offered 247 15.1.13.3 Recent developments 248 15.1.13.3.1 Product Launch 248 15.1.13.3.2 Deals 248 15.1.14 BAYER AG 249 15.1.14.1 Business overview 249 15.1.14.2 Products offered 250 15.1.14.2.1 OTHER DEVELOPMENTS 251 15.1.15 ASPEN NEUROSCIENCE 252 15.1.15.1 Business overview 252 15.1.15.2 Products offered 252 15.1.15.2.1 Other developments 252 15.1.16 LONGEVERON 253 15.1.16.1 Business overview 253 15.1.16.2 Products offered 254 15.1.16.2.1 Other developments 254 15.2 OTHER PLAYERS 255 15.2.1 ATHERSYS, INC. 255 15.2.2 BIORESTORATIVE THERAPIES, INC. 255 15.2.3 KANGSTEM BIOTECH CO., LTD. 256 15.2.4 HOPE BIOSCIENCES 256 15.2.5 CELLULAR BIOMEDICINE GROUP 257 15.2.6 PERSONALIZED STEM CELLS 257 15.2.7 CHIESI FARMACEUTICI S.P.A. 258 15.2.8 CELL TECH PHARMED 258 15.2.9 SUMITOMO PHARMA 259 15.2.10 CYNATA THERAPEUTICS 260 16 RESEARCH METHODOLOGY 261 16.1 RESEARCH DATA 261 16.1.1 SECONDARY DATA 262 16.1.2 PRIMARY DATA 262 16.2 MARKET ESTIMATION METHODOLOGY 264 16.2.1 MARKET SIZE ESTIMATION 264 16.2.2 INSIGHTS OF PRIMARY EXPERTS 266 16.2.3 TOP-DOWN APPROACH 267 16.3 MARKET GROWTH RATE PROJECTIONS 268 16.4 MARKET BREAKDOWN AND DATA TRIANGULATION 270 16.5 RESEARCH ASSUMPTIONS 271 16.6 RESEARCH LIMITATIONS 271 16.7 RISK ASSESSMENT 272 17 APPENDIX 273 17.1 DISCUSSION GUIDE 273 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277 17.3 CUSTOMIZATION OPTIONS 279 17.4 RELATED REPORTS 279 17.5 AUTHOR DETAILS 280
圖表清單 List of Tables & Figures
TABLE 1 STEM CELL THERAPY MARKET: IMPACT OF PORTER'S FIVE FORCES 45 TABLE 2 STEM CELL THERAPY MARKET: IMPACT OF PORTER'S FIVE FORCES 53 TABLE 3 STEM CELL THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 59 TABLE 4 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 59 TABLE 5 INDICATIVE SELLING PRICE, BY REGION, 2025 60 TABLE 6 STEM CELL THERAPY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 61 TABLE 7 MESOBLAST IMPROVES OUTCOMES IN STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH MSC-BASED THERAPY 63 TABLE 8 BLUEROCK THERAPEUTICS ADVANCES REGENERATIVE TREATMENT FOR PARKINSON'S DISEASE USING STEM CELL-DERIVED NEURONS 64 TABLE 9 US-ADJUSTED RECIPROCAL TARIFF RATES 64 TABLE 10 SUPPLY CHAIN ANALYSIS: ROLE OF COMMERCIAL-SCALE/KEY MANUFACTURERS 69 TABLE 11 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 69 TABLE 12 KEY CDMO CAPACITY ADDITIONS 70 TABLE 13 KEY SPONSOR CAPACITY ADDITIONS 71 TABLE 14 GLOBAL KEY STEM CELL THERAPY PRODUCT SALES (USD MN) 72 TABLE 15 KEY PIPELINE PRODUCTS IN STEM CELL THERAPY MARKET (AS OF 2025) 75 TABLE 16 KEY STEM CELL THERAPY PIPELINE CANDIDATES & INDICATION EXPANSIONS 75 TABLE 17 DISCONTINUED/DEPRIORITIZED STEM CELL THERAPY PIPELINE CANDIDATES 76 TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN STEM CELL THERAPY MARKET 78 TABLE 19 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN STEM CELL THERAPY MARKET 79 TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 23 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83 TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 89 TABLE 25 KEY BUYING CRITERIA, BY END USER 90 TABLE 26 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024-2035 (USD MILLION) 94 TABLE 27 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 95 TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 95 TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 95 TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96 TABLE 31 LATIN AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96 TABLE 32 MIDDLE EAST: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 96 TABLE 33 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 97 TABLE 34 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 97 TABLE 35 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 98 TABLE 36 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 98 TABLE 37 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 98 TABLE 38 LATIN AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99 TABLE 39 MIDDLE EAST: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99 TABLE 40 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 99 TABLE 41 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2024-2035 (USD MILLION) 100 TABLE 42 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 100 TABLE 43 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101 TABLE 44 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101 TABLE 45 LATIN AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 101 TABLE 46 MIDDLE EAST: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 102 TABLE 47 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2024-2035 (USD MILLION) 102 TABLE 48 STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2024-2035 (USD MILLION) 103 TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 103 TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 103 TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104 TABLE 52 LATIN AMERICA: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104 TABLE 53 MIDDLE EAST: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 104 TABLE 54 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 105 TABLE 55 STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY REGION, 2024-2035 (USD MILLION) 105 TABLE 56 NORTH AMERICA: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 106 TABLE 57 EUROPE: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 106 TABLE 58 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 106 TABLE 59 LATIN AMERICA: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 107 TABLE 60 MIDDLE EAST: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 107 TABLE 61 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR EMBRYONIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 107 TABLE 62 STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY REGION, 2024-2035 (USD MILLION) 108 TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 108 TABLE 64 EUROPE: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 109 TABLE 65 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 109 TABLE 66 LATIN AMERICA: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 109 TABLE 67 MIDDLE EAST: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 110 TABLE 68 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR TISSUE-SPECIFIC STEM CELLS, BY COUNTRY, 2024-2035 (USD MILLION) 110 TABLE 69 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION 2024-2035 (USD MILLION) 110 TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 111 TABLE 71 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 111 TABLE 72 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 111 TABLE 73 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 112 TABLE 74 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2024-2035 (USD MILLION) 112 TABLE 75 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 20240.02035 (USD MILLION) 112 TABLE 76 STEM CELL THERAPY MARKET, BY TYPE, 2024- 2035 (USD MILLION) 114 TABLE 77 STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY REGION, 2024-2035 (USD MILLION) 114 TABLE 78 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115 TABLE 79 EUROPE: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115 TABLE 80 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 115 TABLE 81 LATIN AMERICA: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116 TABLE 82 MIDDLE EAST: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116 TABLE 83 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR ALLOGENEIC STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 116 TABLE 84 STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY REGION, 2024-2035 (USD MILLION) 117 TABLE 85 NORTH AMERICA: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 117 TABLE 86 EUROPE: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118 TABLE 87 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118 TABLE 88 LATIN AMERICA: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 118 TABLE 89 MIDDLE EAST: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 119 TABLE 90 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR AUTOLOGOUS STEM CELL THERAPY, BY COUNTRY, 2024-2035 (USD MILLION) 119 TABLE 91 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 121 TABLE 92 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2024–2035 (USD MILLION) 122 TABLE 93 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 122 TABLE 94 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 122 TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123 TABLE 96 LATIN AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123 TABLE 97 MIDDLE EAST: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 123 TABLE 98 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 124 TABLE 99 STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY REGION, 2024–2035 (USD MILLION) 124 TABLE 100 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 125 TABLE 101 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 125 TABLE 102 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 125 TABLE 103 LATIN AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 126 TABLE 104 MIDDLE EAST: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 126 TABLE 105 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR WOUNDS & SURGERIES, BY COUNTRY, 2024–2035 (USD MILLION) 126 TABLE 106 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024–2035 (USD MILLION) 127 TABLE 107 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 127 TABLE 108 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128 TABLE 109 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128 TABLE 110 LATIN AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 128 TABLE 111 MIDDLE EAST: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 129 TABLE 112 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 129 TABLE 113 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2035 (USD MILLION) 130 TABLE 114 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 130 TABLE 115 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 130 TABLE 116 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 131 TABLE 117 LATIN AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 131 TABLE 118 MIDDLE EAST: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 131 TABLE 119 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 132 TABLE 120 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2035 (USD MILLION) 132 TABLE 121 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 133 TABLE 122 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 133 TABLE 123 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 133 TABLE 124 LATIN AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 134 TABLE 125 MIDDLE EAST: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 134 TABLE 126 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2035 (USD MILLION) 134 TABLE 127 STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY REGION, 2024–2035 (USD MILLION) 135 TABLE 128 NORTH AMERICA: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 135 TABLE 129 EUROPE: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136 TABLE 130 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136 TABLE 131 LATIN AMERICA: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 136 TABLE 132 MIDDLE EAST: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 137 TABLE 133 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR DIABETES & METABOLIC DISEASES, BY COUNTRY, 2024–2035 (USD MILLION) 137 TABLE 134 STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2024–2035 (USD MILLION) 137 TABLE 135 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138 TABLE 136 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138 TABLE 137 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 138 TABLE 138 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139 TABLE 139 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139 TABLE 140 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 139 TABLE 141 STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 141 TABLE 142 STEM CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2024–2035 (USD MILLION) 141 TABLE 143 NORTH AMERICA: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 142 TABLE 144 EUROPE: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 142 TABLE 145 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 142 TABLE 146 LATIN AMERICA: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143 TABLE 147 MIDDLE EAST: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143 TABLE 148 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2035 (USD MILLION) 143 TABLE 149 STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY REGION, 2024–2035 (USD MILLION) 144 TABLE 150 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 144 TABLE 151 EUROPE: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 145 TABLE 152 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 145 TABLE 153 LATIN AMERICA: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 145 TABLE 154 MIDDLE EAST: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 146 TABLE 155 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR SPECIALTY/STEM CELL CLINICS, BY COUNTRY, 2024–2035 (USD MILLION) 146 TABLE 156 STEM CELL THERAPY MARKET FOR OTHER END USERS, BY REGION, 2024–2035 (USD MILLION) 147 TABLE 157 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 147 TABLE 158 EUROPE: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 147 TABLE 159 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 148 TABLE 160 LATIN AMERICA: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 148 TABLE 161 MIDDLE EAST: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 148 TABLE 162 GCC COUNTRIES: STEM CELL THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2035 (USD MILLION) 149 TABLE 163 STEM CELL THERAPY MARKET, BY REGION, 2024–2035 (USD MILLION) 151 TABLE 164 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 152 TABLE 165 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 153 TABLE 166 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 153 TABLE 167 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 153 TABLE 168 NORTH AMERICA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 154 TABLE 169 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 154 TABLE 170 US: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 154 TABLE 171 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 155 TABLE 172 US: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 155 TABLE 173 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 156 TABLE 174 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 156 TABLE 175 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 156 TABLE 176 CANADA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 157 TABLE 177 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 158 TABLE 178 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 158 TABLE 179 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 158 TABLE 180 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 159 TABLE 181 EUROPE: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 159 TABLE 182 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 160 TABLE 183 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 160 TABLE 184 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 161 TABLE 185 GERMANY: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 161 TABLE 186 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 162 TABLE 187 UK: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 162 TABLE 188 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 162 TABLE 189 UK: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 163 TABLE 190 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 163 TABLE 191 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 163 TABLE 192 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 164 TABLE 193 FRANCE: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 164 TABLE 194 ITALY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 165 TABLE 195 ITALY: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 165 TABLE 196 ITALY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 165 TABLE 197 ITALY: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 166 TABLE 198 SPAIN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 166 TABLE 199 SPAIN: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 166 TABLE 200 SPAIN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 167 TABLE 201 SPAIN: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 167 TABLE 202 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 168 TABLE 203 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 168 TABLE 204 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 168 TABLE 205 REST OF EUROPE: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 169 TABLE 206 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 169 TABLE 207 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 170 TABLE 208 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 170 TABLE 209 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 170 TABLE 210 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 171 TABLE 211 CHINA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 171 TABLE 212 CHINA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 171 TABLE 213 CHINA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 172 TABLE 214 CHINA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 172 TABLE 215 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 173 TABLE 216 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 173 TABLE 217 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 173 TABLE 218 JAPAN: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 174 TABLE 219 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 174 TABLE 220 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 174 TABLE 221 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 175 TABLE 222 INDIA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 175 TABLE 223 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 176 TABLE 224 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 176 TABLE 225 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 176 TABLE 226 SOUTH KOREA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 177 TABLE 227 AUSTRALIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 177 TABLE 228 AUSTRALIA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 177 TABLE 229 AUSTRALIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 178 TABLE 230 AUSTRALIA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 178 TABLE 231 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 179 TABLE 232 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 179 TABLE 233 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 179 TABLE 234 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 180 TABLE 235 LATIN AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 180 TABLE 236 LATIN AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 180 TABLE 237 LATIN AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 181 TABLE 238 LATIN AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 181 TABLE 239 LATIN AMERICA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 181 TABLE 240 BRAZIL: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 182 TABLE 241 BRAZIL: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 182 TABLE 242 BRAZIL: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 183 TABLE 243 BRAZIL: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 183 TABLE 244 MEXICO: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 184 TABLE 245 MEXICO: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 184 TABLE 246 MEXICO: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 184 TABLE 247 MEXICO: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 185 TABLE 248 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 185 TABLE 249 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 185 TABLE 250 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 186 TABLE 251 REST OF LATIN AMERICA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 186 TABLE 252 MIDDLE EAST: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 186 TABLE 253 MIDDLE EAST: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 187 TABLE 254 MIDDLE EAST: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 187 TABLE 255 MIDDLE EAST: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 187 TABLE 256 MIDDLE EAST: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 188 TABLE 257 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 188 TABLE 258 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 188 TABLE 259 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 189 TABLE 260 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 189 TABLE 261 GCC COUNTRIES: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 189 TABLE 262 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 190 TABLE 263 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 190 TABLE 264 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 191 TABLE 265 SAUDI ARABIA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 191 TABLE 266 UAE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 192 TABLE 267 UAE: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 192 TABLE 268 UAE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 192 TABLE 269 UAE: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 193 TABLE 270 REST OF GCC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 193 TABLE 271 REST OF GCC: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 193 TABLE 272 REST OF GCC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 194 TABLE 273 REST OF GCC: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 194 TABLE 274 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 195 TABLE 275 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 195 TABLE 276 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 195 TABLE 277 REST OF MIDDLE EAST: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 196 TABLE 278 AFRICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2024–2035 (USD MILLION) 196 TABLE 279 AFRICA: STEM CELL THERAPY MARKET, BY TYPE, 2024–2035 (USD MILLION) 196 TABLE 280 AFRICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2024–2035 (USD MILLION) 197 TABLE 281 AFRICA: STEM CELL THERAPY MARKET, BY END USER, 2024–2035 (USD MILLION) 197 TABLE 282 STRATEGIES ADOPTED BY KEY PLAYERS IN STEM CELL THERAPY MARKET, 2023−2026 198 TABLE 283 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION 202 TABLE 284 STEM CELL THERAPY MARKET: REGION FOOTPRINT 206 TABLE 285 STEM CELL THERAPY MARKET: CELL SOURCE FOOTPRINT 207 TABLE 286 STEM CELL THERAPY MARKET: TYPE FOOTPRINT 208 TABLE 287 STEM CELL THERAPY MARKET: THERAPEUTIC APPLICATION FOOTPRINT 209 TABLE 288 STEM CELL THERAPY MARKET: KEY STARTUPS/SMES 212 TABLE 289 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 213 TABLE 290 STEM CELL THERAPY MARKET: PRODUCT LAUNCHES/APPROVALS, JANUARY 2023–MAY 2026 216 TABLE 291 STEM CELL THERAPY MARKET: DEALS, JANUARY 2023–MAY 2026 217 TABLE 292 VERICEL CORPORATION: COMPANY OVERVIEW 218 TABLE 293 VERICEL CORPORATION: PRODUCTS OFFERED 219 TABLE 294 VERICEL CORPORATION: PRODUCT APPROVAL, JANUARY 2023–MAY 2026 220 TABLE 295 MESOBLAST: COMPANY OVERVIEW 221 TABLE 296 MESOBLAST: PRODUCTS OFFERED 222 TABLE 297 MESOBLAST: PRODUCTS PIPELINE 222 TABLE 298 MESOBLAST: PRODUCT APPROVAL, JANUARY 2023–MAY 2026 223 TABLE 299 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW 225 TABLE 300 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED 226 TABLE 301 MEDIPOST: COMPANY OVERVIEW 228 TABLE 302 MEDIPOST: PRODUCTS OFFERED 229 TABLE 303 MEDIPOST: PRODUCT PIPELINE 229 TABLE 304 MEDIPOST: DEALS, JANUARY 2023–MAY 2026 229 TABLE 305 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 230 TABLE 306 CO.DON GMBH: COMPANY OVERVIEW 232 TABLE 307 CO.DON GMBH: PRODUCTS OFFERED 232 TABLE 308 SMITH+NEPHEW: COMPANY OVERVIEW 234 TABLE 309 SMITH+NEPHEW: PRODUCTS OFFERED 235 TABLE 310 ANTEROGEN CO., LTD.: COMPANY OVERVIEW 236 TABLE 311 ANTEROGEN CO., LTD.: PRODUCTS OFFERED 236 TABLE 312 CORESTEMCHEMON INC.: COMPANY OVERVIEW 237 TABLE 313 CORESTEMCHEMON INC.: PRODUCTS OFFERED 238 TABLE 314 CORESTEMCHEMON INC: PRODUCT PIPELINE 238 TABLE 315 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY OVERVIEW 239 TABLE 316 VERTEX PHARMACEUTICALS INCORPORATED: PRODUCTS PIPELINE 240 TABLE 317 VERTEX PHARMACEUTICALS INCORPORATED: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 240 TABLE 318 PHARMICELL CO., LTD: COMPANY OVERVIEW 241 TABLE 319 PHARMICELL CO., LTD: PRODUCTS OFFERED 241 TABLE 320 PHARMICELL CO., LTD: PRODUCT PIPELINE 242 TABLE 321 PHARMICELL CO., LTD: DEALS, JANUARY 2023–MAY 2026 242 TABLE 322 HOLOSTEM TERAPIE AVANZATE SRL: COMPANY OVERVIEW 243 TABLE 323 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCTS OFFERED 243 TABLE 324 STEMPEUTICS RESEARCH PVT LTD.: COMPANY OVERVIEW 244 TABLE 325 STEMPEUTICS RESEARCH PVT LTD.: PRODUCTS OFFERED 244 TABLE 326 STEMPEUTICS RESEARCH PVT LTD.: PRODUCT PIPELINE 245 TABLE 327 STEMPEUTICS RESEARCH PVT LTD.: DEALS, JANUARY 2023–MAY 2026 245 TABLE 328 CIPLA LIMITED: COMPANY OVERVIEW 246 TABLE 329 CIPLA LIMITED: PRODUCTS OFFERED 247 TABLE 330 CIPLA LIMITED: PRODUCT LAUNCH, JANUARY 2023–MAY 2026 248 TABLE 331 CIPLA LIMITED: DEALS, JANUARY 2023–MAY 2026 248 TABLE 332 BAYER AG: COMPANY OVERVIEW 249 TABLE 333 BAYER AG: PRODUCTS PIPELINE 250 TABLE 334 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 251 TABLE 335 ASPEN NEUROSCIENCE: COMPANY OVERVIEW 252 TABLE 336 ASPEN NEUROSCIENCE: PRODUCTS PIPELINE 252 TABLE 337 ASPEN NEUROSCIENCE: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 252 TABLE 338 LONGEVERON: COMPANY OVERVIEW 253 TABLE 339 LONGEVERON: PRODUCTS PIPELINE 254 TABLE 340 LONGEVERON: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 254 TABLE 341 ATHERSYS, INC.: COMPANY OVERVIEW 255 TABLE 342 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW 255 TABLE 343 KANGSTEM BIOTECH CO., LTD.: COMPANY OVERVIEW 256 TABLE 344 HOPE BIOSCIENCES: COMPANY OVERVIEW 256 TABLE 345 CELLULAR BIOMEDICINE GROUP: COMPANY OVERVIEW 257 TABLE 346 PERSONALIZED STEM CELLS: COMPANY OVERVIEW 257 TABLE 347 CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW 258 TABLE 348 CELL TECH PHARMED: COMPANY OVERVIEW 258 TABLE 349 SUMITOMO PHARMA: COMPANY OVERVIEW 259 TABLE 350 CYNATA THERAPEUTICS: COMPANY OVERVIEW 260 TABLE 351 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 269 FIGURE 1 STEM CELL THERAPY MARKET SEGMENTATION & REGIONAL SCOPE 31 FIGURE 2 STEM CELL THERAPY MARKET: YEARS CONSIDERED 32 FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 36 FIGURE 4 GLOBAL STEM CELL THERAPY MARKET, 2024–2035 36 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN STEM CELL THERAPY MARKET, 2023–2026 37 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF STEM CELL THERAPY MARKET 38 FIGURE 7 HIGH-GROWTH SEGMENTS IN STEM CELL THERAPY MARKET, 2026–2035 39 FIGURE 8 EUROPE TO REGISTER HIGHEST CAGR IN STEM CELL THERAPY MARKET DURING FORECAST PERIOD 40 FIGURE 9 RISING UNMET MEDICAL NEEDS IN RARE, CHRONIC, AND DEGENERATIVE DISEASES ACCELERATING GROWTH OF STEM CELL THERAPY MARKET 41 FIGURE 10 ALLOGENEIC STEM CELL THERAPY SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA 42 FIGURE 11 UK TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 42 FIGURE 12 AUTOLOGUS STEM CELL THERAPY TO DOMINATE MARKET IN 2026 43 FIGURE 13 STEM CELL THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 44 FIGURE 14 STEM CELL THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS 52 FIGURE 15 STEM CELL THERAPY PRODUCTS MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 16 STEM CELL THERAPY MARKET: ECOSYSTEM ANALYSIS 58 FIGURE 17 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT (2025) 60 FIGURE 18 INDICATIVE SELLING PRICE, BY REGION (2025) 60 FIGURE 19 STEM CELL THERAPY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 62 FIGURE 20 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 63 FIGURE 21 STEM CELL THERAPY MARKET: SUPPLY CHAIN ANALYSIS 68 FIGURE 22 IMPACT OF AI/GEN AI ON STEM CELL THERAPY MARKET 77 FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 89 FIGURE 24 KEY BUYING CRITERIA, BY END USER 89 FIGURE 25 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 152 FIGURE 26 EUROPE: STEM CELL THERAPY MARKET SNAPSHOT 157 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN STEM CELL THERAPY MARKET, 2023–2025 (USD MILLION) 200 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN STEM CELL THERAPY MARKET (2025) 201 FIGURE 29 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 204 FIGURE 30 STEM CELL THERAPY MARKET: COMPANY FOOTPRINT 205 FIGURE 31 STEM CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 211 FIGURE 32 EV/EBITDA OF KEY VENDORS 214   FIGURE 33 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 214 FIGURE 34 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 215 FIGURE 35 VERICEL CORPORATION: COMPANY SNAPSHOT (2025) 219 FIGURE 36 MESOBLAST: COMPANY SNAPSHOT (2025) 221 FIGURE 37 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2024) 226 FIGURE 38 MEDIPOST: COMPANY SNAPSHOT (2023) 228 FIGURE 39 SMITH+NEPHEW: COMPANY SNAPSHOT (2025) 235 FIGURE 40 CORESTEMCHEMON INC.: COMPANY SNAPSHOT (2022) 237 FIGURE 41 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT (2025) 240 FIGURE 42 CIPLA LIMITED: COMPANY SNAPSHOT (2025) 247 FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2025) 250 FIGURE 44 LONGEVERON: COMPANY SNAPSHOT (2025) 254 FIGURE 45 STEM CELL THERAPY MARKET: RESEARCH DESIGN 261 FIGURE 46 STEM CELL THERAPY MARKET: BREAKDOWN OF PRIMARIES 263 FIGURE 47 STEM CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 264 FIGURE 48 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 265 FIGURE 49 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF VERICEL CORPORATION (2025) 265 FIGURE 50 MARKET SIZE VALIDATION THROUGH PRIMARY SOURCES 266 FIGURE 51 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 267 FIGURE 52 STEM CELL THERAPY MARKET GROWTH PROJECTIONS 268 FIGURE 53 STEM CELL THERAPY MARKET: DATA TRIANGULATION 270

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們